Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2015 by Mount Sinai School of Medicine
Sponsor:
Collaborators:
Myeloproliferative Disorders-Research Consortium
Roche Pharma AG
QIAGEN Marseille
Information provided by (Responsible Party):
Ronald Hoffman, Mount Sinai School of Medicine
ClinicalTrials.gov Identifier:
NCT01259856
First received: December 7, 2010
Last updated: March 5, 2015
Last verified: March 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2024
  Estimated Primary Completion Date: June 2024 (Final data collection date for primary outcome measure)